Cue Biopharma (FRA:1UC0) E10: €-36.07 (As of Mar. 2026)


FRA:1UC0 Cue Biopharma Inc FRA:1UC0
57 GF Score
Price €25.92
GF Value €51.06
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Cue Biopharma E10?

Cue Biopharma FRA:1UC0 57 E10 is €-36.07 as of Mar. 2026. GuruFocus rates FRA:1UC0 with a GF Score™ of 57/100 and a GF Value™ of €51.06 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Cue Biopharma's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.934. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-36.07 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-25), Cue Biopharma's current stock price is €25.92. Cue Biopharma's E10 for the quarter that ended in Mar. 2026 was €-36.07. Cue Biopharma's Shiller PE Ratio of today is .


Cue Biopharma  (FRA:1UC0) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Cue Biopharma E10 Related Terms


Cue Biopharma E10 Historical Data

* Premium members only.

The historical data trend for Cue Biopharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cue Biopharma E10 Chart

Cue Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cue Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -36.07

FRA:1UC0 vs TELO, ACET, AARD: E10 Comparison

For the Biotechnology subindustry, Cue Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cue Biopharma Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cue Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cue Biopharma's Shiller PE Ratio falls into.


FRA:1UC0
57GF Score
Cue Biopharma Inc FRA:1UC0
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cue Biopharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cue Biopharma's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.934/330.2130*330.2130
=-0.934

Current CPI (Mar. 2026) = 330.2130.

Cue Biopharma Quarterly Data

per share eps CPI Adj_EPS
201512 0.000 236.525 0.000
201609 -2.621 241.428 -3.585
201612 -3.916 241.432 -5.356
201703 -4.553 243.801 -6.167
201706 -5.709 244.955 -7.696
201709 -6.136 246.819 -8.209
201712 -12.821 246.524 -17.173
201803 -9.002 249.554 -11.912
201806 -9.245 251.989 -12.115
201809 -15.940 252.439 -20.851
201812 -15.295 251.233 -20.103
201903 -14.337 254.202 -18.624
201906 -12.213 256.143 -15.745
201909 -8.444 256.759 -10.860
201912 -9.990 256.974 -12.837
202003 -13.032 258.115 -16.672
202006 -10.123 257.797 -12.967
202009 -8.660 260.280 -10.987
202012 -8.878 260.474 -11.255
202103 -10.332 264.877 -12.881
202106 -8.217 271.696 -9.987
202109 -10.455 274.310 -12.586
202112 -6.638 278.802 -7.862
202203 -11.986 287.504 -13.767
202206 -10.501 296.311 -11.702
202209 -9.393 296.808 -10.450
202212 -10.762 296.797 -11.974
202303 -8.126 301.836 -8.890
202306 -8.030 305.109 -8.691
202309 -6.746 307.789 -7.237
202312 -7.978 306.746 -8.588
202403 -6.900 312.332 -7.295
202406 -5.574 314.175 -5.859
202409 -4.595 315.301 -4.812
202412 -3.725 315.605 -3.897
202503 -4.579 319.799 -4.728
202506 -2.341 322.561 -2.397
202509 -1.789 324.800 -1.819
202512 0.256 324.054 0.261
202603 -0.934 330.213 -0.934

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-36.07 mean?
Cue Biopharma (FRA:1UC0) has a E10 of €-36.07 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Cue Biopharma and its competitors.
Is Cue Biopharma's E10 too high?
Cue Biopharma's current E10 is €-36.07. Overall, Cue Biopharma has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cue Biopharma's E10 compare to TELO and ACET?
Cue Biopharma's E10 of €-36.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Cue Biopharma and its competitors. Cue Biopharma's current E10 is €-36.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cue Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cue Biopharma (FRA:1UC0) is currently considered Possible Value Trap. The stock's GF Value™ is €51.06, compared to a current price of €25.92 — trading 49.2% below its estimated fair value. The current E10 is €-36.07. Cue Biopharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Cue Biopharma (FRA:1UC0), the current E10 is €-36.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cue Biopharma (FRA:1UC0) Overvalued in 2026?

Based on GuruFocus' analysis, Cue Biopharma stock appears to be undervalued. The current stock price of €25.92 is trading 49.2% below its estimated GF Value™ of €51.06. GuruFocus considers Cue Biopharma to be Possible Value Trap.

Key valuation signals for FRA:1UC0:

  • E10: €-36.07
  • GF Value™: €51.06 vs. price of €25.92 (49.2% below fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the FRA:1UC0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cue Biopharma Business Description

Other Exchanges CUE:USA
Address 40 Guest Street, Boston, MA, USA, 02135
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
57GF Score

Get the complete analysis for FRA:1UC0

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€25.92
Price
€51.06
GF Value